Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846960 | 0.94 | HRH3 (0.42) | KMT2AATMHRH3L3MBTL1HSD17B10 | |
| SCHEMBL6851398 | 0.90 | KMT2A (0.40) | KMT2AATMLTA4HEPHX2FLT3 | |
| SCHEMBL6853121 | 0.90 | SMN1; SMN2 (0.43) | KMT2ALTA4HEPHX2ALDH1A1LMNA | |
| SCHEMBL7654772 | 0.84 | ALDH1A1 (0.38) | P2RX7TSHRALDH1A1LMNANPC1 | |
| SCHEMBL6849675 | 0.84 | ALDH1A1 (0.41) | KMT2AATMHRH3L3MBTL1EPHX1 | |
| SCHEMBL6847114 | 0.83 | L3MBTL1 (0.42) | KMT2AL3MBTL1TSHRALDH1A1LMNA | |
| SCHEMBL6849634 | 0.79 | POLB (0.43) | KMT2AP2RX7ALDH1A1LMNANPC1 | |
| SCHEMBL7141811 | 0.78 | NPC1 (0.39) | KMT2AL3MBTL1P2RX7ALDH1A1NPC1 | |
| SCHEMBL6850901 | 0.77 | CCNA2 (0.42) | KMT2AALDH1A1LMNA | |
| SCHEMBL6851432 | 0.71 | P2RX7 (0.38) | KMT2AATMLTA4HL3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6756384-B2 | TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. | NOVO NORDISK A/S (DK) | 2004-06-29 | — | — | US | disclosed |
| US-20030135056-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2003-07-17 | — | — | US | disclosed |
| EP-1268484-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | EP | disclosed |
| US-6437147-B1 | FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM | NOVO NORDISK (DK) | 2002-08-20 | — | — | US | disclosed |
| US-20020058659-A1 | Imidazole compounds | HIGH POINT PHARMACEUTICALS, LLC | 2002-05-16 | — | — | US | disclosed |
| WO-2001068652-A1 | CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135056-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KMT2A 300/4885ATM 2840/4885LTA4H 415/4885 |
| US-20020058659-A1 | Imidazole compounds | HRH3, HRH4, HRH2 | KMT2A 300/4885ATM 2840/4885LTA4H 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.